EGFR and non-small cell lung carcinoma: However, most NSCLC patients develop drug resistance 9–14 months after the initiation of first- and second-generation targeted therapy, and the most common resistance mechanism is caused by EGFR exon20 T790M mutation (incidence ≥ 50%) [10].